Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;56(1):28-40.
doi: 10.1111/apt.16969. Epub 2022 May 14.

Review article: current and emerging therapies for acute alcohol-associated hepatitis

Puru Rattan  1 , Vijay H Shah  1
Affiliations
Review

Review article: current and emerging therapies for acute alcohol-associated hepatitis

Puru Rattan et al. Aliment Pharmacol Ther. 2022 Jul.

Abstract

Background: Alcohol-associated hepatitis is an acute manifestation of alcohol-associated liver disease (ALD) and is associated with 30%-40% mortality at 28 days. Abstinence and corticosteroids are the mainstays of treatment, but the latter only improves short-term mortality, so new and improved therapies remain an unmet need.

Aims: The aim was to review the pathophysiology of alcohol-associated hepatitis and how various targets can be used by current and emerging therapies as treatment.

Methods: A thorough literature review was conducted on acute alcohol-associated hepatitis, current therapies and therapies under investigation.

Results: With the increasing prevalence of alcohol use disorder and ALD, the burden of alcohol-associated hepatitis is also expected to rise. The current understanding of alcohol-associated hepatitis pathophysiology has led to clinical trials of several therapies involving IL-1 antagonism, modification of the gut microbiome and liver regeneration.

Conclusions: Corticosteroid therapy for alcohol-associated hepatitis is restricted in its applicability and has limited efficacy. Developing multidisciplinary, patient-centred care models based on digital health technologies, in combination with continued discovery of novel therapies using multiomics data and computational biology techniques will be necessary to tackle the increasing burden of alcohol-associated hepatitis.

PubMed Disclaimer

References

REFERENCES

    1. Griswold MG, Fullman N, Hawley C, Arian N, Zimsen SRM, Tymeson HD, et al. Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2018;392(10152):1015-35. https://doi.org/10.1016/S0140-6736(18)31310-2
    1. Esser MB, Sherk A, Liu Y, Naimi TS, Stockwell T, Stahre M, et al. Deaths and years of potential life lost from excessive alcohol use-United States, 2011-2015. MMWR Morb Mortal Wkly Rep. 2020;69(39):1428-33. https://doi.org/10.15585/mmwr.mm6939a6
    1. Pollard MS, Tucker JS, Green HD. Changes in adult alcohol use and consequences during the COVID-19 pandemic in the US. JAMA Netw Open. 2020;3(9):e2022942. https://doi.org/10.1001/jamanetworkopen.2020.22942
    1. Shaheen AA, Kong K, Ma C, Doktorchik C, Coffin CS, Swain MG, et al. Impact of the COVID-19 pandemic on hospitalizations for alcoholic hepatitis or cirrhosis in Alberta, Canada. Clin Gastroenterol Hepatol. 2022;20(5):e1170-9. https://doi.org/10.1016/j.cgh.2021.10.030
    1. Cholankeril G, Goli K, Rana A, Hernaez R, Podboy A, Jalal P, et al. Impact of COVID-19 pandemic on liver transplantation and alcohol-associated liver disease in the USA. Hepatology. 2021;74(6):3316-29. https://doi.org/10.1002/hep.32067

LinkOut - more resources